Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Sanofi SA — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.61, while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and VanEck JP Morgan EM Local Currency Bond ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| EMLC | SNY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $52.34 |
52-Week Low | $24.83 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.615, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payments of $0.13-$0.14 per share. Emerging market debt exposure provides yield advantages over developed markets, though volatility remains a consideration.
The outlook for EMLC appears favorable given the Federal Reserve's accommodative stance and emerging market yield premiums. Key opportunities include attractive fixed income returns compared to Treasury bonds, while risks center on emerging market volatility and inflation concerns. The technical bullish signal supports near-term price stability with potential for gradual appreciation.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
